Diana Issacs, PharmD, BCPS, BCACP, BC-ADM, CDCES

Articles

Challenges to Biosimilar Adoption of Insulin Glargine-yfgn

December 01, 2021

Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.

Impact of Interchangeable Insulin Biosimilars on Cost of Biologics

December 01, 2021

Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.

Results of INSTRIDE Studies for Diabetes Management

December 01, 2021

Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.